SLPI and autosomal dominant polycystic kidney disease: Further support for an inflammatory component in ADPKD patients is provided by the aforementioned upregulation of slpi in susceptible mice strains during tolvaptan treatment (Mosedale et al. 2017b), and the significantly greater presence of inflammasome signaling expressed in ADPKD cells (de Almeida et al. 2016).